whatever's happening here, IMHO, we have a strategy that is keeping Bisantrene in the clinic and is getting Bisantrene RC220 into the clinic as soon as is possible in two indications (AML and Breast Cancer) where we know it works and there are three external organisations who are keen to pick it back up for investigator led clinical trials and these are institutions that we have great long term relationships with (MD Anderson & Nagler/Sheba) plus one new one CoG.
Finance strategy needs to be fleshed out but with two Blockbusters (ie $1Bn+ annual revenue)in the clinic the Pennie's will look after themselves
whatever's happening here, IMHO, we have a strategy that is...
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
-0.105(5.74%) |
Mkt cap ! $293.8M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.70 | $240.3K | 138.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 270 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |